• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C1q在肿瘤微环境中作为一种促癌因子发挥作用,与补体激活无关。

C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

作者信息

Bulla Roberta, Tripodo Claudio, Rami Damiano, Ling Guang Sheng, Agostinis Chiara, Guarnotta Carla, Zorzet Sonia, Durigutto Paolo, Botto Marina, Tedesco Francesco

机构信息

Department of Life Sciences, University of Trieste, Trieste 34127, Italy.

Department of Human Pathology, University of Palermo, Palermo 90127, Italy.

出版信息

Nat Commun. 2016 Feb 1;7:10346. doi: 10.1038/ncomms10346.

DOI:10.1038/ncomms10346
PMID:26831747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4740357/
Abstract

Complement C1q is the activator of the classical pathway. However, it is now recognized that C1q can exert functions unrelated to complement activation. Here we show that C1q, but not C4, is expressed in the stroma and vascular endothelium of several human malignant tumours. Compared with wild-type (WT) or C3- or C5-deficient mice, C1q-deficient (C1qa(-/-)) mice bearing a syngeneic B16 melanoma exhibit a slower tumour growth and prolonged survival. This effect is not attributable to differences in the tumour-infiltrating immune cells. Tumours developing in WT mice display early deposition of C1q, higher vascular density and an increase in the number of lung metastases compared with C1qa(-/-) mice. Bone marrow (BM) chimeras between C1qa(-/-) and WT mice identify non-BM-derived cells as the main local source of C1q that can promote cancer cell adhesion, migration and proliferation. Together these findings support a role for locally synthesized C1q in promoting tumour growth.

摘要

补体C1q是经典途径的激活剂。然而,现在人们认识到C1q可以发挥与补体激活无关的功能。在这里,我们表明C1q而非C4在几种人类恶性肿瘤的基质和血管内皮中表达。与野生型(WT)或C3或C5缺陷小鼠相比,携带同基因B16黑色素瘤的C1q缺陷(C1qa(-/-))小鼠肿瘤生长较慢且生存期延长。这种效应并非归因于肿瘤浸润免疫细胞的差异。与C1qa(-/-)小鼠相比,WT小鼠中发生的肿瘤显示C1q早期沉积、更高的血管密度以及肺转移数量增加。C1qa(-/-)和WT小鼠之间的骨髓(BM)嵌合体确定非BM来源的细胞是C1q的主要局部来源,C1q可促进癌细胞的黏附、迁移和增殖。这些发现共同支持局部合成的C1q在促进肿瘤生长中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/1070b98c71e9/ncomms10346-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/c657809b555b/ncomms10346-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/f2782eca55a5/ncomms10346-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/ef8149a20276/ncomms10346-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/d3c06ca0011b/ncomms10346-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/18e30fc06190/ncomms10346-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/1070b98c71e9/ncomms10346-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/c657809b555b/ncomms10346-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/f2782eca55a5/ncomms10346-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/ef8149a20276/ncomms10346-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/d3c06ca0011b/ncomms10346-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/18e30fc06190/ncomms10346-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/913c/4740357/1070b98c71e9/ncomms10346-f6.jpg

相似文献

1
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.C1q在肿瘤微环境中作为一种促癌因子发挥作用,与补体激活无关。
Nat Commun. 2016 Feb 1;7:10346. doi: 10.1038/ncomms10346.
2
Expression of complement system components during aging and amyloid deposition in APP transgenic mice.补体系统成分在衰老和 APP 转基因小鼠淀粉样沉积中的表达。
J Neuroinflammation. 2009 Nov 17;6:35. doi: 10.1186/1742-2094-6-35.
3
Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.肿瘤细胞劫持巨噬细胞产生的补体 C1q 以促进肿瘤生长。
Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.
4
Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.表达裂解C3的膜蛋白酶p65的人黑色素瘤细胞补体抗性的分子基础
Cancer Res. 1993 Feb 1;53(3):592-9.
5
Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells.用野生型骨髓细胞重建C1q缺陷(C1qa-/-)小鼠的补体功能。
J Immunol. 2001 Oct 1;167(7):4033-7. doi: 10.4049/jimmunol.167.7.4033.
6
Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice.补体与酒精性肝病:C1q在小鼠乙醇诱导性肝损伤发病机制中的作用
Gastroenterology. 2010 Aug;139(2):664-74, 674.e1. doi: 10.1053/j.gastro.2010.04.041. Epub 2010 Apr 21.
7
Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation.聚乙醇酸诱导的炎症:水解作用及由此导致的补体激活的作用
Tissue Eng. 2006 Feb;12(2):301-8. doi: 10.1089/ten.2006.12.301.
8
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation.C1q与凋亡细胞及细胞小泡的直接结合会诱导补体激活。
Eur J Immunol. 2002 Jun;32(6):1726-36. doi: 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R.
9
Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation.前沿:C1q可独立于C3激活预防肾小球肾炎的发生。
J Immunol. 1999 May 15;162(10):5676-9.
10
Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration.视网膜下巨噬细胞产生经典补体激活物 C1q,导致局灶性视网膜变性进展。
Mol Neurodegener. 2018 Aug 20;13(1):45. doi: 10.1186/s13024-018-0278-0.

引用本文的文献

1
Radiotherapy Upregulates the Expression of Membrane-Bound Negative Complement Regulator Proteins on Tumor Cells and Limits Complement-Mediated Tumor Cell Lysis.放射治疗上调肿瘤细胞膜结合负性补体调节蛋白的表达并限制补体介导的肿瘤细胞裂解。
Cancers (Basel). 2025 Jul 18;17(14):2383. doi: 10.3390/cancers17142383.
2
Upregulated BAP31 Links to Poor Prognosis and Tumor Immune Microenvironment in Breast Cancer.上调的BAP31与乳腺癌的不良预后和肿瘤免疫微环境相关。
Int J Mol Sci. 2025 Jun 21;26(13):5975. doi: 10.3390/ijms26135975.
3
Role of Innate Immunity in Cancer.

本文引用的文献

1
Emerging and Novel Functions of Complement Protein C1q.补体蛋白C1q的新出现及新颖功能
Front Immunol. 2015 Jun 29;6:317. doi: 10.3389/fimmu.2015.00317. eCollection 2015.
2
Complement System Part II: Role in Immunity.补体系统第二部分:在免疫中的作用。
Front Immunol. 2015 May 26;6:257. doi: 10.3389/fimmu.2015.00257. eCollection 2015.
3
Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response.补体是放疗诱导的肿瘤特异性免疫和临床反应的核心介质。
先天免疫在癌症中的作用。
Adv Exp Med Biol. 2025;1476:309-337. doi: 10.1007/978-3-031-85340-1_13.
4
The Complement System.补体系统
Adv Exp Med Biol. 2025;1476:147-198. doi: 10.1007/978-3-031-85340-1_7.
5
Proteomic Landscape of Colorectal Cancer Derived Liver Metastasis Reveals Three Distinct Phenotypes With Specific Signaling and Enhanced Survival.结直肠癌肝转移的蛋白质组学图谱揭示了具有特定信号传导和延长生存期的三种不同表型。
Mol Cell Proteomics. 2025 Jul 4;24(8):101026. doi: 10.1016/j.mcpro.2025.101026.
6
Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma.组蛋白乙酰化调节剂的综合多组学分析确定ASH1L为骨肉瘤的一种新型侵袭性标志物。
Discov Oncol. 2025 Jun 12;16(1):1070. doi: 10.1007/s12672-025-02920-6.
7
The role of complement C1q in atrial fibrillation: a marker for disease progression and surgical outcomes.补体C1q在心房颤动中的作用:疾病进展和手术结果的标志物。
Front Cardiovasc Med. 2025 May 2;12:1512187. doi: 10.3389/fcvm.2025.1512187. eCollection 2025.
8
Non-canonical extracellular complement pathways and the complosome paradigm in cancer: a scoping review.癌症中的非经典细胞外补体途径与补体体范式:一项范围综述
Front Immunol. 2025 Apr 30;16:1519465. doi: 10.3389/fimmu.2025.1519465. eCollection 2025.
9
The complement system and kidney cancer: pathogenesis to clinical applications.补体系统与肾癌:从发病机制到临床应用
J Clin Invest. 2025 May 1;135(9). doi: 10.1172/JCI188351.
10
Bilirubin metabolism in relation to cancer.胆红素代谢与癌症的关系。
Front Oncol. 2025 Apr 11;15:1570288. doi: 10.3389/fonc.2025.1570288. eCollection 2025.
Immunity. 2015 Apr 21;42(4):767-77. doi: 10.1016/j.immuni.2015.03.009. Epub 2015 Apr 14.
4
Prognostic stromal gene signatures in breast cancer.乳腺癌中的预后性基质基因特征
Breast Cancer Res. 2015 Feb 21;17(1):23. doi: 10.1186/s13058-015-0530-2.
5
Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.治疗与疾病中的补体:用基于抗体的疗法调节补体系统
Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17.
6
PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.PTX3 是一种外在的肿瘤抑制因子,调节癌症中补体依赖性炎症。
Cell. 2015 Feb 12;160(4):700-714. doi: 10.1016/j.cell.2015.01.004.
7
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.癌症单克隆抗体治疗中补体的调节及其活性的调控
MAbs. 2014;6(5):1133-44. doi: 10.4161/mabs.29670. Epub 2014 Oct 30.
8
Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.突变型 p53 通过与肿瘤抑制因子 DAB2IP 的相互作用,重新编程癌细胞中的 TNF 信号通路。
Mol Cell. 2014 Dec 4;56(5):617-29. doi: 10.1016/j.molcel.2014.10.013. Epub 2014 Nov 13.
9
Mechanisms of disseminated cancer cell dormancy: an awakening field.播散性癌细胞休眠的机制:一个觉醒的领域。
Nat Rev Cancer. 2014 Sep;14(9):611-22. doi: 10.1038/nrc3793. Epub 2014 Aug 14.
10
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.肿瘤诱导的全身性环境作为癌症进展和转移的关键调节者。
Nat Cell Biol. 2014 Aug;16(8):717-27. doi: 10.1038/ncb3015.